Biosimilar Pipeline Targets $414 Billion in Sales
Fresenius' deal with WuXi Biologics gives it access to up to 37 candidates over the next decade.
Updated on Nov. 2, 2026 in Biotech
Fresenius has signed a biosimilar development agreement with WuXi Biologics, a China-based company, giving Fresenius exclusive access to up to 37 identified biosimilar candidates over the next decade. The development is announced; the candidates are in development, not approved products.
Why it matters
The identified candidates address more than €370 billion ($414 billion) in originator sales, and the deal could expand Fresenius' molecules from 29 to as many as 66 by the next decade. Fresenius expects to raise its long-term Biopharma ambitions significantly.
The portfolio spans 13 therapeutic areas and includes monoclonal and bispecific antibodies, antibody-drug conjugates and fusion proteins. The figures describe the size of the candidate pool and addressable sales, not clinical or regulatory results for any molecule.
The players
Fresenius
German healthcare company whose Biopharma unit develops and sells biosimilar medicines.
WuXi Biologics
China-based biologics contract developer and manufacturer specializing in antibodies and other complex protein drugs.
The details
Fresenius signed a development agreement for biosimilar drugs with WuXi Biologics, a China-based company. Biosimilar drugs are drugs that are very close to already approved drugs, developed to match a reference product's structure and performance. The pipeline includes monoclonal antibodies (lab-made immune proteins), bispecific antibodies (which bind two targets at once), antibody-drug conjugates (antibodies linked to toxic payloads), and fusion proteins.
Timeline
Monday, November 2, 2026: Fresenius announced the WuXi Biologics agreement.
2026: Fresenius confirmed financial targets for the year.
Over the next decade: Fresenius gains exclusive access to up to 37 biosimilar candidates.
The Tech Race
The agreement places Fresenius among drugmakers pursuing large biosimilar portfolios through outside development partners rather than in-house pipelines alone. The race is measured by how many originator molecules can be covered by a single partnership.
The deal does not change availability for patients now, since the candidates are in development and no timeline for approval was given. Patients and prescribers would see any resulting products only after regulatory review in each market.
The takeaway
Watch whether Fresenius and WuXi Biologics disclose which of the 37 candidates enter clinical development first and on what timeline. Those milestones will show how quickly the pipeline turns into filed products.
Further reading
For the wider field, explore Biotech coverage of drug development partnerships.
